XTINBEQ
LIVE

Serial Number

98555925

Owner

Celgene Corporation

Attorney

Marilyn F. Kelly

Filing Date

May 17, 2024

Add to watchlist:

No watchlists yet
View on USPTO

XTINBEQ Trademark

Serial Number: 98555925

XTINBEQ is a trademark filed by Celgene Corporation on May 17, 2024. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

Celgene Corporation (883 trademarks)

7 Powder Horn Drive
Warren, NJ 07059

Entity Type: 03

Trademark Details

Filing Date

May 17, 2024

Registration Date

Not Registered

Published for Opposition

September 16, 2025

Goods & Services

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressant preparations, pharmaceutical antibodies for medical use, and immunotherapy preparations for the treatment of cancer; cytokine inhibitory drugs for human use being pharmaceutical preparations for the treatment of cancer; anticoagulants for human use; pharmaceutical preparations for human use that modulate the immune system for the treatment of immune-system related diseases and disorders; pharmaceutical and biological preparations for human use for immunotherapy, namely T-cell therapy preparations for the treatment of cancer; pharmaceutical and biological preparations for human use, namely, stem cells for medical use; pharmaceutical preparations for human use for the treatment or prevention of COVID-19, coronavirus disease, and respiratory diseases and disorders; pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of COVID-19, coronavirus disease, and respiratory diseases and disorders; pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use; pharmaceutical preparations for human use for the treatment of neuropsychiatric disorders; therapeutic radiopharmaceutical preparations for human use for the treatment of cancer and solid tumors; diagnostic radiopharmaceutical preparations for human use; diagnostic preparations for human use for medical purposes; radiopharmaceutical preparations for human use in the nature of imaging and detection agents for diagnosing and monitoring cancer; biological preparations for human use in the nature of radio-isotope markers for therapeutic or diagnostic use; pharmaceutical preparations for human use for the treatment of cystic fibrosis

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 28, 2026 EXRA
SOU EXTENSION 1 GRANTED
Apr 27, 2026 EX1G
SOU EXTENSION 1 FILED
Apr 27, 2026 EXT1
SOU TEAS EXTENSION RECEIVED
Apr 27, 2026 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 11, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 16, 2025 NPUB
PUBLISHED FOR OPPOSITION
Sep 16, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 10, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 13, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Aug 13, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 13, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Aug 13, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Aug 13, 2025 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 13, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 13, 2025 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jun 13, 2025 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Mar 13, 2025 GNFN
FINAL REFUSAL E-MAILED
Mar 13, 2025 GNFR
FINAL REFUSAL WRITTEN
Mar 13, 2025 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 24, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 24, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 24, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 22, 2024 GNRN
NON-FINAL ACTION E-MAILED
Nov 22, 2024 GNRT
NON-FINAL ACTION WRITTEN
Nov 22, 2024 CNRT
ASSIGNED TO EXAMINER
Nov 21, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 19, 2024 NWOS
NEW APPLICATION ENTERED
May 17, 2024 NWAP